More news ahead
Over the past few weeks, Cantargia has presented positive interim data from
the ongoing CANFOUR trial, which has significantly strengthened our
conviction in a successful outcome of ph IIa. The full readout is expected
within the coming months, but the company has, on the back of the recent
findings, already started planning to advance the development of CAN04 in
both NSCLC and PDAC. During Q4, we expect Novartis to present data from
its ongoing ph III trial for Canakinumab, which will provide further insight
into targeting the IL-1 system for cancer treatment. We increase our DCF-
based fair value range to SEK 48-54 (24-27) per share and see several
valuation triggers ahead.
Generalt om Commissioned Research: Bemærk, at man bør se bort fra eventuelle kursestimater i såkaldt commissioned research, og den underliggende analyse skal også tolkes med forsigtighed, da negative aspekter ikke nødvendigvis fremhæves.